FTRE
Fortrea Holdings Inc.
Biotechnology · Healthcare · United States
23.14
close · 2026-10-29
value
58
cheaper than peers58
quality
46
stronger fundamentals46
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 0.82× | 99 |
| forward P/E | 20.46× | 55 |
| price to book | 4.20× | 42 |
| EV to EBITDA | 34.69× | 32 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 2.6% | 82 |
| return on equity | -15.3% | 76 |
| revenue growth | -4.5% | 30 |
| debt to equity | 213.2% | 13 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $278.9M |
| employees | 14,000 |
| first trade | 2023-06-16 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -10.81 | -3.67 | -0.04 | 2.11 |
| free cash flow | $88.3M | $237.3M | $128.1M | $28.3M |
| net income | -$986.2M | -$328.5M | -$25.2M | $186.2M |
| revenue | $2.72B | $2.70B | $2.84B | $2.84B |
| unusual items | -$868.9M | -$60.7M | -$20.9M | -$37.7M |